Tuberculosis Is In The Way To Shorten The Treatment Course For Patients

Tuberculosis Is In The Way To Shorten The Treatment Course For Patients

Tuberculosis (TB) is known as a deadly disease that is infectious to the whole body. This disease is affected by the lungs and also the other parts of the body. This disease doesn’t show any kind of symptoms as it is known as “latent tuberculosis”. TB (tuberculosis) will spread when the infected person sneezes or coughs.

Tuberculosis Is In The Way To Shorten The Treatment Course For Patients

According to researchers, there is a six months regimen of multidrug for infected people, this process had not changed in the last 40 years. The long course treatment may feel uncomfortable for the patients rather than making it short-term helps the patients to get treated quickly.

Tuberculosis Is In The Way To Shorten The Treatment Course For Patients

A research team from the South Carolina of medical university (MUSC) investigated a report about a short-term treatment regimen with the drug named rifapentine which is more effective for the TB disease. To decrease the patient’s adherence, treatment should be shortened which follows an important step in the medication.

In the year 2019, 1.4 million people were died because of tuberculosis (TB). World health organization had estimated that one-quarter of people are infected with TB. These people have a lifetime risk of 5 percent to 10 percent for the development of total TB disease. People with HIV are the most targeted people for TB attacks.

Susan Dorman, M.D., and professor at medicine college (MUSC) said that TB is mostly affected to adult people at the prime stage of their lives. He said that this disease may suffer their families with poverty as the charges for treatment is high at a cost that disrupts their family,

According to researchers, TB is treatable and preventable as multidrug are used in their medication treatment. TB remains a top health threat in public. The current treatment for TB-infected people is a regimen of six to nine months of course. TB can also be treated with several antibiotics and antidrug.

Dorman said that “patient adherence will be the huge taxing charges worldwide which follow a main factor of drug-resistant for TB and are most expensive, toxic, and time-consuming treatment for the patients. The main element is the reduction of time for treating tuberculosis is the public demand right now”.

Dorman explained himself about the reduction of time on treating patients which can be advantageous for all the people where money, time, and burden can be saved. Thereby patient adherence can also be reduced. 

MUSC had worked with two different centers of disease control and prevention (CDC) as well as health trials of a national institution. Working together they found a way of shortening the treatment with a complete cure of TB disease.

The whole research team is now concentrating on the drug named “rifapentine”. This drug is already familiar with the protocol of TB treatment but, this new drug lasts for longer in the human body which can be treated in very little time. Researching team had spent over 15 years with a case study to prove that this drug can create wonders in less time.

Later, many trials were conducted by the research team and gave a conclusion with how much dosage should be given to the patient with the estimated period. These trials are followed for a single patient for up to 12 months.

The results were revealed as six months regimen should be followed up with two drugs named “rifapentine” and “moxifloxacin” and these two drugs were tolerated by all age groups of patients. This work represents a standout landmark for tuberculosis (TB). More trials would be done to shorten the period, even more, said Dorman.

Leave a Reply

Your email address will not be published. Required fields are marked *

San Franciso Played A Vital Role In The AIDS Fight Previous post San Franciso Played A Vital Role In The AIDS Fight
Researchers Works On How Killer T Cells Works As Control Resistors On Cancer Cells Next post Researchers Works On How Killer T Cells Works As Control Resistors On Cancer Cells